PRPF19 and hepatocellular carcinoma: Since p38 blockade significantly overcomes therapy resistance of sorafenib in HCC mouse model [37], our work here provides possibilities that targeting Prp19 would be a promising therapeutic modality alone or together with other treatments for HCC.